Ipsen Material Announcements

Key highlights

Ipsen completes acquisition of Albireo, expanding the scope of its Rare Disease portfolio

– 02 March 2023 – 1 mins read

02 March 2023 – 1 mins read

Ipsen completes acquisition of Albireo, expanding the scope of its Rare Disease portfolio

PARIS, FRANCE, 3 March 2023 – Ipsen (Euronext: IPN: ADR: IPSEY) today announced it has completed the acquisition of Albireo Pharma, Inc., a leading innovator in bile-acid modulators to treat rare liver conditions. The acquisition enriches Ipsen’s Rare Disease portfolio, with…

Filter

Period

Filter by

Reset

Showing: 1 – 05 of 16 Corporate News

Show

Sort

– 01 December 2020

01 December 2020

Capital Markets Day 2020 – announcement

Debiopharm and Ipsen extend their strategic Decapeptyl® (triptorelin) partnership for another 15 years

– 12 June 2019

12 June 2019

Debiopharm and Ipsen extend their strategic Decapeptyl® (triptorelin) partnership for another 15 years

Debiopharm and Ipsen extend and strengthen their ongoing collaboration to ensure patient access to Decapeptyl® for the treatment of certain urological, gynecological and pediatric conditions